全球高血壓市場：2007年至2023年

Abstract

The market for hypertensives - led by the angiotensin II antagonists - is one of the largest and most profitable in the global pharmaceutical market, with total anti-hypertensive sales of $36600m in 2006. Hypertension, or high blood pressure, is a worldwide epidemic: by 2025 visiongain predict that worldwide there will be more than 1.5 billion sufferers of this disease. Modern lifestyles, such as poor diet and lack of exercise, are the main contributory factors to elevated blood pressure. Consequently, the incidence and prevalence of hypertension are increasing rapidly in both developed and developing countries.

• In 2005, The Lancet reported that more than 330 million adults in Europe and North America suffer from high blood pressure
• With many more in the developed world the Hypertension market is still relatively untapped
• According to the World Health Organisation, approximately 80% of people with high blood pressure have additional uncontrolled cardiovascular risks
• Hypertension is also strongly age-dependent, with older people being far more susceptible
• Aging populations worldwide therefore constitute a further driver in this prominent market

This is a market you cannot afford to ignore. Are new, potentially successful drugs going to change the market within the next 10 to 15 years? This report will tell you.

The World Hypertension Market 2007-2023 concentrates on the following essential aspects of the market:

• Overview of treatments in the hypertension sector
• Key industrial players in anti-hypertensive treatments
• Forecast of the world anti-hypertensive market from 2007-2023, including forecasts of the leading therapeutic agents
• Forecasts for anti-hypertensive sales in the leading national pharmaceutical markets
• Drivers and opportunities in the anti-hypertensive treatment market
• Restraints and threats in the anti-hypertensive treatment market
• Key opinions from experts in the healthcare sector, academia and medical practice
• Coverage of pipeline developments

The World Hypertension Market 2007-2023 examines the market for antihypertensive drugs critically, through comprehensive primary and secondary research. In addition to consultation with experts in medical practice, academia and industry, this research involved a detailed study of policy documents, industrial reports and relevant news. Importantly, visiongain also applied techniques such as financial forecasting, SWOT analyses and qualitative projections. The result is a comprehensive market-based report with detailed analysis and informed opinion.

Why you should buy this report:

• To receive a comprehensive analysis of the prospects for anti-hypertensive treatments from 2007-2023
• To discover predicted revenues, growth rates and other key metrics for anti-hypertensive treatments from 2006-2023
• To receive the views of experts in the field of hypertension
• To determine the forces that influence the market for anti-hypertensive treatments:
  • competitive characteristics of the market
  • Drivers
  • Restraints
  • Strengths, weaknesses, opportunities and threats
• To find out where the hypertension market is heading - both technologically and commercially

The hypertension market is one of the largest in the global pharmaceutical industry, with continued prospects for high revenue generation and market growth. Nevertheless, the hypertension market is facing great challenges in terms of strong internal competition and patent expiration with a concomitant generic threat. Clearly, there are also unmet needs in this market that require urgent attention. While the angiotensin II antagonists have provided an improved balance of efficacy and tolerability in recent years, it is possible that even newer classes of antihypertensive - such as the renin inhibitors - will also provide great therapeutic and commercial scope. Given the great challenges of treating hypertension, continued investment into the development of improved treatments is required, as well as basic scientific research into the disorder. Recent developments in both the pharmaceutical industry and the public sector provide scope for optimism.

Unique benefits to you when you order this report

• Primary research throughout. You will not find this information anywhere else
• Report stored in your reading room for ever
• Full searchable report when you buy the company or corporate editions
• Copies can be printed off for offline reading
• Packed with charts, analysis, figures, graphs and tables

Table of Contents

1. Executive Summary - Hypertension is a Serious Cause of Mortality Worldwide

2. Introduction to Hypertension

• 2.1 An Overview of Hypertension
• 2.2 Symptoms of Hypertension and Diagnosis of the Condition
• 2.3 Causes of Hypertension
• 2.4 Primary Hypertension
• 2.5 Secondary Hypertension
• 2.6 Pulmonary Hypertension
• 2.7 Epidemiology of Hypertension
• 2.8 Links with Other Disorders
• 2.9 The Treatment of Hypertension
  • 2.9.1 Countering Hypertension Through Changes in Diet and Lifestyle - A First Line of Attack
  • 2.9.2 Treatment Targets and the Selection of Drugs
  • 2.9.3 Beta Blockers
  • 2.9.4 Angiotensin Converting Enzyme (ACE) Inhibitors
  • 2.9.5 Calcium-Channel Blockers
  • 2.9.6 Angiotensin II Blockers
  • 2.9.7 Alpha Blockers
  • 2.9.8 Diuretics
  • 2.9.9 Tekturna/Rasilez (aliskiren) - a First-In-Class Renin Inhibitor
  • 2.9.10 Other Drugs
• 2.10 The Treatment of Pulmonary Hypertension
• 2.11 The Prospects for Patients

3 The World Hypertension Market, 2007-2023

• 3.1 Growing Demand and Shifting Internal Dynamics in the World Anti-hypertensive Market, 2007-2023
• 3.2 Novartis to Become the Leading Company in the Hypertension Market by the End of the Decade
• 3.3 Angiotensin II Blockers to Continue Their Domination of the Anti-hypertensive Market, 2006 Onwards
• 3.4 Other Classes of Anti-hypertensive Drug Will Display High Revenues during 2006-2012
• 3.5 Calcium Channel Blockers - Declining Revenues due to Heightened Competition
• 3.6 Angiotensin Converting Enzyme (ACE) Inhibitors - Will This Class Be Superseded by the Angiotensin II Blockers?
• 3.7 Beta-Blockers - Carving a Secure Niche in a Highly Competitive Market?
• 3.8 Alpha Blockers Will Maintain a Respected Position in the Hypertension Market
• 3.9 Competition in the Anti-hypertensive Market to Become Increasingly Intense
• 3.10 Monotherapy or Combination Therapy?
• 3.11 Diuretic Agents Retain Importance

4. The World Market for Angiotensin II Blockers, 2007-2023

• 4.1 Angiotensin II Blockers - Strong Growth Leads to Continuing Predominance in the Market
  • 4.1.1 The Angiotensin II Blockers Will Benefit From More Secure Patent Protection Than The Other Classes of Antihypertensives
  • 4.1.2 Other Advantages of Angiotensin II Blockers That Confer Important Benefits in the Market
• 4.2 Diovan to Take Market Leadership from Norvasc by 2007
  • 4.2.1 Diovan/Co-Diovan Benefits From High Prescription Rates in the US Market
  • 4.2.2 Paediatric Exclusivity Granted by FDA in 2007
  • 4.2.3 Approval for Reduction of Cardiovascular Death
  • 4.2.4 Diovan Benefits from Further Clinical Studies
  • 4.2.5 Recent Support from The European Society of Cardiology
  • 4.2.6 The AVVANCE Trial Provided Further Support for Diovan
  • 4.2.7 The NAVIGATOR Trial for Improved Glucose Tolerance
• 4.3 Cozaar/Hyzaar - High Revenues Followed by Decline
  • 4.3.1 Development for Diabetic Nephropathy - The RENAAL study
  • 4.3.2 FDA Approval for LVH
  • 4.3.3 Diabetic Nephropathy Approval in Japan During 2006
  • 4.3.4 Further Developments for Cozaar/Hyzaar
• 4.4 Avapro/Aprovel/Avalide to Maintain Steady Growth
  • 4.4.1 Avaprovel/Avapro Benefits from Continuing Development
  • 4.4.2 BMS Places High Emphasis on Irbesartan
  • 4.4.3 Sublicensing of Irbesartan for Japanese Market
• 4.5 Blopress - Another Strong Performer
  • 4.5.1 Additional FDA Approval for Blopress
• 4.6 Micardis Will Become a Leading Blockbuster by the End of the Decade
  • 4.6.1 Micardis Shows Potential Metabolic Benefits
  • 4.6.2 Micardis Benefits from Further Clinical Studies
  • 4.6.3 Further Clinical Studies May Confer a Market Advantage to Micardis
• 4.7 Benicar/Olmetec' s Revenue Growth Set to Continue Steadily
  • 4.7.1 Further Licensing Agreements for Benicar
  • 4.7.2 Promising Results from Further Clinical Study
  • 4.7.3 Sankyo Used Licensing Deals for International Marketing
  • 4.7.4 The ORIENT Study and Other Developments
• 4.8 Exforge Will Achieve Blockbuster Revenues by The End of the Decade
• 4.9 Other Agents Will Have an Increasing Presence in the Angiotensin II Blockers Market

5 The World Market for Calcium Channel Blockers, 2006-2023

• 5.1 Increased Competition Will Lower Revenues Among the Calcium Channel Blockers
• 5.2 Norvasc - 2006 Hypertension Market Leader Set to Lose Dominance to Leading Angiotensin II Blockers
  • 5.2.1 Norvasc is Going To Suffer from Prescribing Shift to Angiotensin II Antagonists
  • 5.2.2 Norvasc Has Faced Serious Patent Challenges
  • 5.2.3 Norvasc Benefits from Further Clinical Testing
  • 5.2.4 Active Ingredient in Norvasc Combined with that of Lipitor to Form Dual Action Cardiovascular Drug
  • 5.2.5 New Combination Product Exforge Will Draw Sales from Both Norvasc and Diovan
• 5.3 Lotrel Reaches Blockbuster Revenue Levels then Declines
  • 5.3.1 Lotrel is a Prominent Combination Product
  • 5.3.2 The ACCOMPLISH Study for High Risk Hypertension
• 5.4 Adelat Faces a Gradual Decline
  • 5.4.1 Adelat is a Fine Example of Lifecycle Prolongation
• 5.5 Amlodin Follows the General Trend for Calcium Blockers
• 5.6 Other Agents Will Exert An Increasing Presence in the Calcium Blocker Market

6. The World Market for Beta-Blockers, 2006-2023

• 6.1 Beta Blockers Will Retain Their Niche Despite a Marked Decline in Sales
  • 6.1.1 Uses and Limitations of Beta Blockers That Affect Their Position In The Market
• 6.2 Toprol-XL/Seloken Will Remain the Most Important Beta Blocker from 2007 Onwards
  • 6.2.1 Approval for Cardiac Failure
  • 6.2.2 Toprol-XL Faces Patent Challenges
• 6.3 Coreg Will Be The Second Largest Beta blocker from 2007 Onwards
  • 6.3.1 Coreg Faces Increasing Generic Competition
  • 6.3.2 Coreg May Benefit From Further Clinical Studies
  • 6.3.3 Licensing of Carvedilol
• 6.4 Concor/Bisoprolol
  • 6.4.1 Phase III Trials in Japan for Chronic Heart Failure
• 6.5 Other Agents Will Have an Increasing Presence in the Beta Blocker Market

7 The World Market for ACE Inhibitors, 2006-2023

• 7.1 How Well Will The ACE Inhibitors Resist Competition From The Angiotensin II Blockers?
  • 7.1.1 ACE Inhibitors Will Retain Prominence in The Market
• 7.2 Delix/Tritace Will Retain Predominance in this Class
  • 7.2.1 Licensing Agreements for International Distribution
  • 7.2.2 Further Clinical Studies and Life Cycle Management to Confer Benefits to Delix/Tritace
• 7.3 Altace Will Maintain Second Place in the ACE inhibitor Market
• 7.4 Vasotec/Vaseretic - This Older Drug Will Face Decline
  • 7.4.1 Enalapril is a Versatile ACE Inhibitor
  • 7.4.2 Additional Clinical Studies and Product Development to Benefit Vasotec
• 7.5 Other Agents Will Have an Increasing Presence in the ACE inhibitors Market

8. The World Market for Alpha Blockers, 2006-2023

• 8.1 Alpha blockers Will Lose Prominence in the Hypertension Market
  • 8.1.1 Alpha Blockers Are Also Used to Treat BPH
  • 8.1.2 Limitations On The Use of Alpha Blockers Influence Their Performance in The Market
• 8.2 Cardura Will Dominate the Alpha Blocker Class
• 8.3 Other Agents Will Have an Increasing Presence in the Alpha blocker Market

9 The World Market for Other Hypertensive Agents, 2006-2023

• 9.1 Will New Antihypertensive Classes Such As the Renin Inhibitors Challenge the Established Agents?
• 9.2 Tracleer - a Blockbuster of the Future
  • 9.2.1 Tracleer is the First of the Endothelin Receptor Antagonists and a Major Advance in the Treatment of Pulmonary Arterial Hypertension
  • 9.2.2 European Approval for Digital Ulcers In Patients With Systemic Sclerosis And Ongoing Digital Ulcer Disease
  • 9.2.3 Trials for Congestive Heart Failure
• 9.3 Tekturna/Rasilez - The Trailblazer of the New Renin Inhibitor Class
  • 9.3.1 Novartis Will Gain a Significant First-Mover Advantage With Aliskiren
  • 9.3.2 Approval and Launch of Aliskiren in the US
  • 9.3.3 EU Approval for Aliskiren in June 2007
• 9.4 Other Agents Will Have an Increasing Presence in This Group

10. An Analysis of Factors That Influence the Hypertension Market

• 10.1 SWOT Analysis of the Hypertension Market
• 10.2 An Expanding Patient Population Constitutes the Principal Driver in the Hypertension Market
• 10.3 The Hypertension Market Has Opportunities for Continuing Growth
• 10.4 Changes in Blood Pressure Treatment Guidelines - Can Both Patients and Drug Companies Benefit?
• 10.5 Advances in Technology Are Likely to Bring Benefits to the Market
• 10.6 The Principal Restraints in the Hypertension Market
• 10.7 To What Extent is the Hypertension Market Threatened by Generic Substitutes?
• 10.8 What Unmet Market Needs Exist in the Hypertension Market? - Experts Provide Their Views
  • 10.8.1 Resistant Hypertension Constitutes a Major Limitation of Present Treatments
  • 10.8.2 Important Patient Sub-Populations: Potential For Companies To Increase Market Leverage Through Product Differentiation
• 10.9 Comparative Studies - A Two Edged Sword

11. A Geographical Breakdown of the World Hypertension Market

• 11.1 The US Will Lead a High Revenue Global Market in 2010
• 11.2 The Prevalence of Hypertension Worldwide - Many Hypertensive People Currently Untreated or Under-treated
• 11.3 There is An Urgent Requirement To Expand the Treatment of Hypertension on a Global Scale

12. Pipeline Developments in Hypertension

• 12.1 Submitted and Approved Agents for Hypertension
  • 12.1.1 Tekturna HCT
  • 12.1.2 Cleviprex
  • 12.1.3 CS 8663
• 12.2 Phase III Developments for Hypertension
  • 12.2.1 Coreg CR Combination
  • 12.2.2 CS 866AZ
  • 12.2.3 Actelion 1
  • 12.2.4 Darusentan
• 12.3 Phase II Developments for Hypertension
  • 12.3.1 Ilepatril
  • 12.3.2 TAK 491
  • 12.3.3 PST 2238
  • 12.3.4 PF 489791
  • 12.3.5 Fimasartan
  • 12.3.6 SPP 635
  • 12.3.7 Daglutril
  • 12.3.8 NCX 4016
  • 12.3.9 SLx 2101
  • 12.3.10 Protherics' Immunotherapeutic Vaccine
  • 12.3.11 TBC 3711
  • 12.3.12 SB 221
  • 12.3.13 CYT006-AngQb
  • 12.3.14 MC-4232
  • 12.3.15 MK 0736
  • 12.3.16 MC-4262 from Medicure
• 12.4 Early Stage Developments in Hypertension
  • 12.4.1 MC 4262
  • 12.4.2 Actelion' s Renin Inhibitor Development with Merck & Co
  • 12.4.3 SPP 1148
  • 12.4.4 MC-1
• 12.5 The Renin Inhibitors May Be One of the Few Other Drugs To Challenge The Angiotensin II Inhibitors During The Forecast Period

13 Conclusions: Hypertension Constitutes a Large Drugs Market with Scope for Expansion Worldwide List of Figures

• 13.1 Hypertension is a Serious, Growing Problem Worldwide
• 13.2 Hypertension Constitutes a High Revenue Market with Continuing Growth Potential
• 13.3 Hypertension Drugs will Achieve High Revenues in all the Major Geographical Markets from 2005-2010
• 13.4 The Pipeline for Hypertension Drugs is Strong
• 13.5 Continuing Public and Private Sector Investment is Required

List of Tables

• Table 2.1, Categories for Blood Pressure in Adults
• Table 2.2, Leading Beta-Blockers to Treat Hypertension
• Table 2.3, Leading ACE Inhibitors to Treat Hypertension
• Table 2.4, Leading Calcium Channel Blockers to Treat Hypertension
• Table 2.5, Leading Angiotensin II Blockers to Treat Hypertension
• Table 2.6, Leading Alpha Blockers to Treat Hypertension
• Table 3.1, Blockbuster Drugs in the World Hypertension Market, 2006
• Table 3.2, World Revenues ($m) for the Leading Hypertension Drugs, by Class, 2006-2012
• Table 3.3, World Revenues ($m) for the Leading Hypertension Drugs, by Class, 2013-2023
• Table 3.4, World Market Revenue ($m), 6-Year CAGR (%) and Market Share (%) for Hypertension Drugs by Class, 2006 & 2012 Table 3.5, World Market Revenue ($m), 2012, and CAGR (%) for Hypertension Drugs by Class, 2012-2023
• Table 3.6, World Market Revenue ($m) and Change (%), 2006 and 2012
• Table 4.1, World Revenues ($m) for Angiotensin II Blockers, 2006-2012
• Table 4.2, World Revenues ($m) for Angiotensin II Blockers, 2013-2023
• Table 4.3, Patent Expiry for Leading Angiotensin II Blockers, 2007
• Table 4.4, World Market Revenue ($m) and Market Share (%) and 6-Year CAGR (%) for Angiotensin II Blockers, 2006 & 2012 Table 4.5, World Market Revenue ($m), 2012, and CAGR (%) for Angiotensin II Blockers, 2012-2023
• Table 5.1, World Revenues ($m) for Calcium Channel Blockers, 2006-2012
• Table 5.2, World Revenues ($m) for the Calcium Channel Blockers, 2013-2023
• Table 5.3, Patent Expiry for Calcium Channel Blockers to Treat Hypertension
• Table 5.4, World Market Revenue ($m) and Market Share (%) and 6-Year CAGR (%) for Calcium Channel Blockers, 2006 & 2012 Table 5.5, World Market Revenue ($m), 2012, and CAGR (%) for Calcium Channel Blockers, 2012-2023
• Table 6.1, World Revenues ($m) for Beta Blockers, 2006-2012
• Table 6.2, World Revenues ($m) for the Beta Blockers, 2013-2023
• Table 6.3, Patent Expiry for Beta-Blockers to Treat Hypertension
• Table 6.4, World Market Revenue ($m) and Market Share (%) and 6-Year CAGR (%) for Beta Blockers, 2006 & 2012
• Table 6.5, World Market Revenue ($m), 2012, and CAGR (%) for Beta Blockers, 2012-2023
• Table 7.1, World Revenues ($m) for ACE Inhibitors, 2006-2012
• Table 7.2, World Revenues ($m) for ACE Inhibitors, 2013-2023
• Table 7.3, Patent Expiry for ACE Inhibitors to Treat Hypertension
• Table 7.4, World Market Revenue ($m) and Market Share (%) and 6-Year CAGR (%) for ACE Inhibitors, 2006 & 2012
• Table 7.5, World Market Revenue ($m), 2012, and CAGR (%) for ACE Inhibitors, 2012-2023
• Table 8.1, World Revenues ($m) for Alpha Blockers, 2006-2012 Table 8.2, World Revenues ($m) for Alpha Blockers, 2013-2023 Table 8.3, Patent Expiry for Alpha Blockers to Treat Hypertension
• Table 8.4, World Market Revenue ($m) and Market Share (%) and 6-Year CAGR (%) for Alpha Blockers, 2006 & 2012
• Table 8.5, World Market Revenue ($m), 2012, and CAGR (%) for Alpha Blockers, 2012-2023
• Table 9.1, World Revenues ($m) for Other Agents, 2006-2012
• Table 9.2, World Revenues ($m) for Other Agents, 2013-2023
• Table 9.3, World Market Revenue ($m) and Market Share (%) and 6-Year CAGR (%) for Other Agents, 2006 & 2012
• Table 9.4, World Market Revenue ($m), 2012, and CAGR (%) for Other Agents, 2012-2023
• Table 10.1, Leading Anti-hypertensive Drugs That Face The Greatest Threat From Generic Competition, 2005
• Table 11.1, Estimated Hypertensive Patient Populations by Country, 2004
• Table 11.2, Estimated Total Sales ($m) For Hypertension Drugs by Leading National Market, 2006 and 2012
• Table 13.1, World Revenues ($m) for the Leading Hypertension Drugs, by Class, 2006-2012
• Table 13.2, World Revenues ($m) for the Leading Hypertension Drugs, by Class, 2013-2023
• Table 13.3, Estimated Total Sales ($m) For Hypertension Drugs by Leading National Market, 2006 and 2012

List of Figures

• Figure 3.1, World Revenues ($m) for the Leading Hypertension Drugs, by Class, 2006-2023
• Figure 3.2, World Revenues ($m) for the Leading Hypertension Drugs, by Class, 2006-2023
• Figure 3.3, World Market Share (%) for Hypertension by Class, 2006
• Figure 3.4, World Market Share (%) for Hypertension by Class, 2012
• Figure 3.5, Changes ($m) in World Revenues for the Classes of Hypertension Drugs, 2006-2012
• Figure 3.6, Changes (%) in World Revenues for the Classes of Hypertension Drugs, 2006-2012
• Figure 4.1, Total World Revenues ($m) for Angiotensin II Blockers, 2006-2023
• Figure 4.2, World Revenues ($m) for the Angiotensin II Blockers by Leading Product, 2006-2023
• Figure 4.3, World Market Share (%) for Angiotensin II Blockers, 2006
• Figure 4.4, World Market Share (%) for the Angiotensin II Blockers, 2012
• Figure 4.5, World Diovan Revenues ($m), 2006-2023
• Figure 4.6, World Cozaar/Hyzaar Revenues ($m), 2006-2023
• Figure 4.7, World Avapro/Aprovel and Avalide Revenues ($m), 2006-2023
• Figure 4.8, World Blopress Revenues ($m), 2006-2023
• Figure 4.9, World Micardis Revenues ($m), 2006-2023
• Figure 4.10, World Benicar/Olmetec Revenues ($m), 2006-2023
• Figure 4.11, World Exforge Revenues ($m), 2006-2023
• Figure 4.12, World Revenues ($m) for Other Angiotensin II Blockers, 2006-2023
• Figure 5.1, Total World Revenues ($m) for Calcium Blockers, 2006-2023
• Figure 5.2, World Revenues ($m) for the Calcium Blockers by Leading Product, 2006-2023
• Figure 5.3, World Market Share (%) for Calcium Blockers, 2006
• Figure 5.4, World Market Share (%) for the Calcium Blockers, 2012
• Figure 5.5, World Norvasc Revenues ($m), 2006-2023
• Figure 5.6, World Lotrel Revenues ($m), 2006-2023
• Figure 5.7, World Adalat Revenues ($m), 2006-2023
• Figure 5.8, World Amlodin Revenues ($m), 2006-2023
• Figure 5.9, World Revenues for Other Calcium Blockers ($m), 2006-2023
• Figure 6.1, Total World Revenues ($m) for Beta Blockers, 2006-2023
• Figure 6.2, World Revenues ($m) for the Beta Blockers by Leading Product, 2006-2023
• Figure 6.3, World Market Share (%) for Beta Blockers, 2006
• Figure 6.4, World Market Share (%) for the Beta Blockers, 2012
• Figure 6.5, World Toprol-XL/Seloken Revenues ($m), 2006-2023
• Figure 6.6, World Coreg Revenues ($m), 2006-2023
• Figure 6.7, World Concor/Bisoprolol Revenues ($m), 2006-2023
• Figure 6.8, World Revenues ($m) for Other Beta Blockers, 2006-2023
• Figure 7.1, Total World Revenues ($m) for ACE Inhibitors, 2006-2023
• Figure 7.2, World Revenues ($m) for the ACE Inhibitors by Leading Product, 2006-2023
• Figure 7.3, World Market Share (%) for ACE Inhibitors, 2006
• Figure 7.4, World Market Share (%) for the ACE Inhibitors, 2012
• Figure 7.5, World Delix/Tritace Revenues ($m), 2006-2023
• Figure 7.6, World Altace Revenues ($m), 2006-2023
• Figure 7.7, World Vasotec/Vaseretic Revenues ($m), 2006-2023
• Figure 7.8, World Revenues ($m) for Other ACE Inhibitors, 2006-2023
• Figure 8.1, Total World Revenues ($m) for Alpha Blockers, 2006-2023
• Figure 8.2, World Revenues ($m) for the Alpha Blockers by Leading Product, 2006-2023
• Figure 8.3, World Market Share (%) for Alpha Blockers, 2006
• Figure 8.4, World Market Share (%) for the Alpha Blockers, 2012
• Figure 8.5, World Cardura Revenues ($m), 2006-2023
• Figure 8.6, World Revenues ($m) for Other Alpha Blockers, 2006-2023
• Figure 9.1, Total World Revenues ($m) for Other Anti-Hypertensives, 2006-2023
• Figure 9.2, World Revenues ($m) for Other Anti-Hypertensives by Leading Product, 2006-2023
• Figure 9.3, World Market Share (%) for Other Anti-Hypertensives, 2006
• Figure 9.4, World Market Share (%) for Other Anti-Hypertensives, 2012
• Figure 9.5, World Tracleer Revenues ($m), 2006-2023
• Figure 9.6, World Tekturna/Rasilez Revenues ($m), 2006-2023
• Figure 9.7, World Revenues ($m) for Other Agents in This Group, 2006-2023
• Figure 10.1, A SWOT Chart for the Hypertension Market, 2005-2010
• Figure 11.1, Estimated Hypertensive Populations by Country, 2004
• Figure 11.2, Revenues ($m) for Hypertension Drugs by Country, 2006
• Figure 11.3, Revenues ($m) for Hypertension Drugs by Country, 2012

Companies Mentioned in This Report

• A Menarini AG
• Abbott
• Actelion
• Altana
• Andrx Pharmaceuticals
• Apotex
• Astellas Phama
• AstraZeneca
• Athena
• Biovail Corporation
• BLI Pharmaceutical Development Ltd
• BNC-Pharmapass LLC
• Boehringer Ingelheim
• Boryung Pharmaceutical Company
• Bristol-Myers Squibb
• CoTherix
• Cytos
• Daiichi Sankyo
• Discovery
• Dr Reddy' s Laboratories
• Ecosol AG
• Encysive Pharmaceuticals
• Eon Labs
• Forest Laboratories
• G. Streuli & Co AG
• Gilead
• GlaxoSmithKline
• Goldshield
• Helvepharm AG
• Ivax Pharmaceuticals
• Janssen Pharmaceutica N.V
• King
• Kowa
• KV Pharmaceutical Company
• Kyowa Hakko Kogyo
• Lederle
• Lexicon Genetics Incorporated
• LifeCycle Pharma
• Lupin
• Medicure
• Medika AG
• Menarini
• Mepha Pharma AG
• Merck & Co
• Merck KGaA
• Mutual Pharmaceutical
• Mylan
• Mylan Bertek Pharmaceuticals
• Mylan Laboratories
• Myogen
• Neopharm
• NicOx
• Novartis
• Par Pharmaceuticals
• Penwest Pharmaceuticals Co
• Pfizer
• Protherics
• Ranbaxy
• Recordati
• Robapharm AG
• Roche
• Sandoz
• Sankyo Pharma
• Sanofi-Aventis
• Santen
• Schering AG
• Schwarz Pharmaceutical
• Sepracor
• Shionogi
• Shire Pharmaceuticals
• Solvay
• Speedel
• Spirig Pharma AG
• SunTen Phytotech
• Surface Logix
• Takeda Pharmaceutical
• Tanabe Seiyaku
• Teva
• The Medicines Company
• Watson
• Wyeth Pharmaceuticals